- EQS-PVR: MorphoSys AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
- EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
- EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
- EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
- EQS-News: MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
- EQS-News: MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
- EQS-News: MorphoSys Out Licenses Pre-Clinical Oncology Program
- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
- EQS-AFR: MorphoSys AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
More ▼
Key statistics
Markit short selling activity
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 34.23m |
Free float | 33.67m |
P/E (TTM) | -- |
Market cap | 650.41m EUR |
EPS (TTM) | -25.23 EUR |
Data delayed at least 15 minutes.
More ▼